Clinical Trials Logo

HER2/Neu Positive clinical trials

View clinical trials related to HER2/Neu Positive.

Filter by:
  • Terminated  
  • Page 1

NCT ID: NCT02774681 Terminated - Clinical trials for Stage IV Breast Cancer

Palbociclib in Treating Patients With Metastatic HER-2 Positive Breast Cancer With Brain Metastasis

Start date: August 31, 2016
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate if the study drug palbociclib has anti-tumor activity against the breast cancer that has spread to the brain and also to determine the overall radiographic response rate in the CNS. Palbociclib is an anti-cancer medication that has been shown to stop cancer cells from growing. It has been approved in hormone positive breast cancer, along with other hormone therapies and has been found to be effective. The preclinical studies suggest that the drug may also have activity in other types of breast cancer, such as HER2 positive breast cancer. The purpose of this study is to see if the study drug is effective in patients with brain metastasis, who have HER2-positive breast cancer.

NCT ID: NCT01319539 Terminated - Clinical trials for Stage IIIA Breast Cancer

MK2206 in Treating Patients With Stage I, Stage II, or Stage III Breast Cancer

Start date: April 2011
Phase: Phase 2
Study type: Interventional

This phase II trial is studies how well Akt inhibitor MK2206 works in treating patients with stage I-III breast cancer that can be removed by surgery. Akt inhibitor MK2206 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

NCT ID: NCT01281163 Terminated - Clinical trials for Stage IV Breast Cancer

Lapatinib Ditosylate and Akt Inhibitor MK2206 in Treating Women With Metastatic Breast Cancer

Start date: January 2011
Phase: Phase 1
Study type: Interventional

This phase I trial studies the side effects and the best dose of lapatinib ditosylate and Akt inhibitor MK2206 in treating women with metastatic breast cancer. Lapatinib ditosylate and Akt inhibitor MK2206 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.